Mode
Text Size
Log in / Sign up
N/A N=21 Randomized Double-blind Treatment

Motivating Occupational Virtual Experiences In Therapy for Kids

Virtual Reality · Occupational Therapy

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Pre Jebsen Taylor Hand Function Test (JTHFT) — 433.9; 294.7 seconds

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MOVE-IT Intervention (Device); UCT Control (Behavioral)
Age
Pediatric · 4+ yrs
Sex
All
Sponsor
Barron Associates, Inc.
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Pre Jebsen Taylor Hand Function Test (JTHFT)
433.9; 294.7
PRIMARY
Post Jebsen Taylor Hand Function Test (JTHFT)
416.6; 268.3
SECONDARY
Pre Pediatric Motor Activity Log (Amount)
1.68; 2.30
SECONDARY
Post Pediatric Motor Activity Log (Amount)
1.80; 2.23
SECONDARY
Pre Pediatric Motor Activity Log (How Well)
1.68; 2.73
SECONDARY
Post Pediatric Motor Activity Log (How Well)
2.25; 2.98
SECONDARY
Pre Intervention Wolf Motor Function Test Time (WMFT-TIME)
24.3; 18.3
SECONDARY
Post Intervention Wolf Motor Function Test Time (WMFT-TIME)
24.1; 24.9
SECONDARY
Pre Intervention Wolf Motor Function Test Functional Assessment (WMFT-FA)
2.95; 3.40
SECONDARY
Post Intervention Wolf Motor Function Test Functional Assessment (WMFT-FA)
3.00; 3.63
SECONDARY
Pre Quality of Upper Extremity Skills Test (QUEST)
67.5; 77.7
SECONDARY
Post Quality of Upper Extremity Skills Test (QUEST)
65.3; 77.4

Summary

A rater-blinded randomized controlled trial (RCT) will be conducted to compare the efficacy of MOVE-IT use in a remotely supervised home exercise program (HEP) to usual care for recovery of upper extremity (UE) function in children with hemiplegia.

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of hemiplegia resulting from cerebral palsy, stroke, or other form of brain injury;
  • Medically stable;
  • Participant has antigravity strength in the affected UE at the elbow to at least 45 degrees of active flexion;
  • Participant has antigravity shoulder strength in the affected UE to at least 30 degrees each in active flexion, abduction/adduction, and 15 degrees in active internal/external rotation when in an upright and seated position;
  • Participant has ability to perform a basic color-matching test and identify characters on a vision chart;
  • Participant must be available to attend study visits during an approximately 3-week participation period;
  • Willingness and ability to comply with scheduled visits and study procedures.

Exclusion Criteria

  • History of uncontrolled seizures;
  • Has received another form of intensive UE therapy, such as CIMT, within the prior 6 months;
  • Unwillingness or inability to understand or follow verbal directions;
  • Diagnosis of moderate to severe cortical-visual impairment that in the judgement of the Principal Investigator could adversely impact the subject's participation;
  • Psychological diagnosis that in the determination of the Principal Investigator could significantly impact subject's participation or that could be aggravated by study participation;
  • Determination that participation would result in over exertion, or significant discomfort or pain;
  • Determination that participation would result in significant agitation or elevated stress;
  • Visual field deficit in either eye that impairs the ability to view the computer monitor.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04510857). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search